Adrenergic beta-AntagonistsMetoprololBisoprololCeliprololPropanolaminesAtenololCalcium Channel BlockersCarteololHospital PlanningBetaxololDiureticsInterleukin-1betaCarbazolesTimololAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsPropranololAcebutololbeta 2-MicroglobulinLabetalolHeart FailureAngiotensin II Type 1 Receptor BlockersPotassium Channel BlockersHypertensionReceptors, Adrenergic, betaAlprenololPindololDrug Therapy, CombinationPractololIntegrin beta3Myocardial InfarctionNew EnglandHeart RateTreatment OutcomeTime FactorsDose-Response Relationship, DrugProstaglandins, SyntheticHydrochlorothiazideSodium Channel BlockersTransforming Growth Factor betaDrug Utilization ReviewBlood PressureAdrenergic alpha-AntagonistsAdministration, TopicalSodium Chloride Symporter InhibitorsDouble-Blind MethodElectrocardiographyClinical Trials as TopicIntegrin alpha5beta1Integrin beta4Angina PectorisProspective StudiesRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsCoronary DiseaseCells, CulturedPractice Guidelines as TopicIntegrin alpha6beta4Cardiomyopathy, DilatedIntegrin beta Chainsbeta 2-Glycoprotein IReceptors, Adrenergic, beta-2Anti-Arrhythmia AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsIntegrin alpha4beta1AspirinEmergency TreatmentPerioperative CareVentricular Dysfunction, LeftEpinephrineIntegrin alpha2beta1Cardiotonic AgentsDrug InteractionsReceptors, Adrenergic, beta-1Cell LineCalciumInterleukin-1Chronic DiseaseAntigens, CD29NifedipineIntegrinsRandom AllocationRNA, MessengerHospitalizationMigraine DisordersGuideline AdherenceIntegrin alpha6beta1Drug UtilizationPropensity ScoreDobutamineDrug CombinationsRats, Sprague-DawleySignal TransductionFollow-Up StudiesExercise TestIntegrin alpha1beta1Drug Administration ScheduleTetrazolesAdrenergic beta-Agonists